Visit
The International Workshop on Myeloma (iwMyeloma) 2021 took place on 25-27 March with VJHemOnc as official media partner. The workshop offered a high-level discussion forum for research leaders in the field of myeloma, to further our understanding of recent advances in myeloma and encouraged interactive discussion.
Presentations and panel discussions with leading experts are now available to watch below.
iwMyeloma 2021
25–27 March 2021 | Virtual Meeting
iwMyeloma 2021
25–27 March 2021 | Virtual Meeting
The International Workshop on Myeloma (iwMyeloma) 2021 took place on 25-27 March with VJHemOnc as official media partner. The workshop offered a high-level discussion forum for research leaders in the field of myeloma, to further our understanding of recent advances in myeloma and encouraged interactive discussion.
Presentations and panel discussions with leading experts are now available to watch below.
Session 1: Drug Resistance and High-Risk Multiple Myeloma
Drug resistant and high-risk MM
Gareth Morgan Perlmutter Cancer Center, NYU Langone Health, New York City, NY, United States
Genomics of SMM
Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States
Molecular definitions of high-risk MM
Leif Bergsagel Mayo Clinic, Phoenix, AZ, United States
Melphalan signatures
Francesco Maura Sylvester Comprehensive Cancer Center, Miami, FL, United States
Genomics of relapse
Niels Weinhold Heidelberg University, Heidelberg, Germany
Segmentation at presentation and relapse
Jonathan Keats TGen, Phoenix, AZ, United States
Genetic resistance to IMiDs
Sarah Gooding Radcliffe Department of Medicine, Oxford, United Kingdom
Session 1 panel discussion
Consensus panel discussion on high-risk multiple myeloma
Session 2: Management of Older Patients and Smoldering Multiple Myeloma
Is there a role for genetic assessment in older patients?
Eileen Boyle NYU Langone Health, New York City, NY, United States
Design of elderly trials and geriatric risk scores
Charlotte Pawlyn The Institute of Cancer Research, London, United Kingdom
Managing elderly patients
Alessandra Larocca A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
Mass spectrometry for monitoring MRD
Angela Dispenzieri Mayo Clinic, Rochester, MN, United States
Interventions and update on current clinical trials for SMM
Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
MGUS in Iceland
Sigurdur Kristinsson University of Iceland, Rekjavik, Iceland
Session 2 panel discussion
Session 3: The Clinical application of T-cell Engagers in Multiple Myeloma
The clinical application of T-cell engagers in MM
Ajai Chari Mount Sinai Medical Center, New York City, NY, United States
Role of BCMA targeted ADC and bi-specifics
Sagar Lonial Winship Cancer Institute of Emory University, Atlanta, GA, United States
Can TCE overcome high-risk MM?
Rafael Fonseca Mayo Clinic, Phoenix, AZ, United States
Combination immunotherapies
Kenneth Anderson Dana-Farber Cancer Institute, Boston, MA, United States
Session 3 panel discussion
Session 4: Cure and the Management of Younger Patients
Cure and the management of younger patients
Jesús San Miguel University of Navarra, Pamplona, Spain
The role of ASCT, tandem ASCT and consolidation
Francesca Gay University of Turin, Turin, Italy
Current and future of management of HR: melphalan flufenamide in rMM
Pieter Sonneveld Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
STaMINA trial update
Sergio Giralt Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Role of consolidation
Philippe Moreau The University Hospital of Nantes, Nantes, France
Maintenance strategies: ixazomib
Faith Davies Perlmutter Cancer Center, NYU Langone Health, New York City, NY, United States
Session 4 panel discussion
Session 5: The Development and Integration of Novel Targets
The development and integration of novel targets
Keith Stewart Princess Margaret Cancer Centre, Ontario, Canada
MCL1, BCL2 inhibition and 1q amp
Lawrence Boise Emory Winship Cancer Institute, Atlanta, GA, United States
MRD, Master study and therapy cessation
Luciano Costa UAB School of Medicine, Birmingham, AL, United States
Biology of residual clones
Bruno Paiva University of Navarra, Pamplona, Spain
anti-CD38 combinations
Peter Voorhees Levine Cancer Institute, Atrium Health, Charlotte, NC, United States
Nuclear exportin inhibitors
Nizar Bahlis Arnie Charbonneau Cancer Institute, Calgary, Canada
Session 5 panel discussion
Session 6: T-Cell Engagement Strategies in 2021; Current Data
T-Cell Engagement Strategies in 2021; current data
Edward Stadtmauer Perelman School of Medicine, Philadelphia, PA, United States
BCMA CAR-T (BMS)
Yi Lin Mayo Clinic, Rochester, MN, United States
BCMA CAR-T (Janssen)
Deepu Madduri The Tisch Cancer Institute, Mount Sinai, New York City, NY, United States
GPRC5D
Niels van de Donk VU University Medical Center, Amsterdam, Netherlands
FCRHL5
Adam Cohen Abramson Cancer Center, Philadelphia, PA, United States
AMG 420 BiTE molecule
Hermann Einsele Würzburg University Hospital, Würzburg, Germany
Managing side effects and integration with existing approaches
Nina Shah University of California, San Francisco, CA, United States
Session 6 panel discussion
Visit the Multiple Myeloma Channel for the latest updates from leading experts
VJHemOnc is intended for Healthcare Professionals onlyBy choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
The content of VJHemOnc is intended for healthcare professionals